UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~September~~June 30, ~~2023~~2024

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission file number: 000-56145

VICAPSYS LIFE SCIENCES, INC.

Florida		91-1930691
(State or Other Jurisdiction of		(IRS Employer
Incorporation or Organization)		Identification Number)

7778 Mcginnis Ferry Rd. #269
7778 Mcginnis Ferry Rd. #270
Suwanee, GA		30024
(Address of Principal Executive Offices)		(Zip Code)

(972) 891-8033

(Registrant’s Telephone Number, Including Area Code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered under Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or has for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s $0.001 par value common stock as of ~~November~~December 1413, ~~2023~~2024, was 32,~~071~~371,299).

Vicapsys Life Sciences, Inc.

TABLE OF CONTENTS

		~~Page~~	Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022	4
	Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023		4
	Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022 (unaudited)	5
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (unaudited)		5
	Consolidated Statements of Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 (unaudited)	6
	Condensed Consolidated Statements of Stockholders’ Deficit for the three and six months ended June 30, 2024 and 2023 (unaudited)		6
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)	7
	Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2024 and 2023 (unaudited)		7
	Notes to Condensed Unaudited Consolidated Financial Statements	8	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risks	25	23
Item 4.	Controls and Procedures	25	23
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	26	24
Item 1A.	Risk Factors	26	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26	24
Item 3.	Defaults Upon Senior Securities	26	24
Item 4.	Mine Safety Disclosures	26	24
Item 5.	Other Information	26	24
Item 6.	Exhibits	26	24
SIGNATURES		27	25

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains certain forward-looking statements that are subject to various risks and uncertainties. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may,” “will,” “should,” “potential,” “intend,” “expect,” “outlook,” “seek,” “anticipate,” “estimate,” “approximately,” “believe,” “could,” “project,” “predict,” or other similar words or expressions. Forward-looking statements are based on certain assumptions, discuss future expectations, describe future plans and strategies, contain financial and operating projections or state other forward-looking information. Our ability to predict results or the actual effect of future events, actions, plans or strategies is inherently uncertain. Although we believe that the expectations reflected in our forward-looking statements are based on reasonable assumptions, our actual results and performance could differ materially from those set forth or anticipated in our forward-looking statements. Factors that could have a material adverse effect on our forward- looking statements and upon our business, results of operations, financial condition, funds derived from operations, cash available for dividends, cash flows, liquidity and prospects include, but are not limited to, the factors referenced in this document, including those set forth below:

	●	our lack of an operating history;
	●	the net losses that we expect to incur as we develop our business;
	●	Obtaining U.S. Food and Drug Administration (“FDA”) or other regulatory approvals or clearances for our technology;
	●	implementing and achieving successful outcomes for clinical trials of our products;
	●	convincing physicians, hospitals and patients of the benefits of our technology and to convert from current technology;
	●	the ability of users of our products (when and as developed) to obtain third-party reimbursement;
	●	any failure to comply with rigorous FDA and other government regulations; and
	●	securing, maintaining and defending patent or other intellectual property protections for our technology.

Forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in Company’s Annual Report filed on Form 10-K filed with the Securities and Exchange Commission on ~~April~~October 1421, ~~2023~~2024, (the “Form 10-K”) ~~for~~ for the fiscal year ended December 31, ~~2022~~2023, as the same may be updated from time to time, including in Part II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any of these forward-looking statements, which reflect our views as of the date of this document. The matters discussed herein and elsewhere in this document could cause our actual results and performance to differ materially from those set forth or anticipated in forward-looking statements. Accordingly, we we cannot guarantee future results or performance. Furthermore, except as required by law, we are under no duty to, and we do not intend to, update any of our forward-looking statements after the date of this document, whether as a result of new information, future events or otherwise.

VICAPSYS LIFE SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September 30, 2023			December 31, 2022
	June 30, 2024			December 31, 2023
Assets
Current Assets:
Cash	$	~~53,532~~-		$	149,~~097~~422
Prepaid expenses		52,280			7,483
Prepaid Expenses		-			30,234
Deferred offering costs		102,674			50,441
Total Current Assets		-			39,656
Total Current Assets		208,486			72,021
Total Assets	$	-		$	39,656
Total Assets	$	208,486		$	72,021
Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable	$	673,179		$	635,183
Cash overdraft	$	86		$	-
Accounts payable, related parties		446,621			272,317
Accounts payable		1,135,905			961,708
Accounts payable, related parties		732,695			537,449
Accounts payable		732,695			537,449
Accrued salaries, related party		115,312			115,312
Short-term note payable		3612,~~789~~546			—18,712
Convertible note payable, net of debt discount		270,463			—
Convertible note payable		449,300			335,156
Total Current Liabilities		12,~~542~~445,~~364~~844			1,~~022~~968,~~812~~337
Stockholders’ Deficit:
Series A Convertible Preferred Stock; par value $0.001; 3,000,000 shares authorized; -0- shares issued and outstanding		—			—
Series A Convertible Preferred Stock; par value $0.0001; 3,000,000 shares authorized; -0- shares issued and outstanding		-			-
Series B Convertible Preferred Stock; par value $0.001; 4,440,000 shares authorized; -0- shares issued and outstanding		—			—
Series B Convertible Preferred Stock; par value $0.0001; 4,440,000 shares authorized; -0- shares issued and outstanding		-			-
Common Stock, par value $0.001; 300,000,000 shares authorized; 32,071,299 and 31,188,460 shares issued and outstanding, respectively		32,071			31,188
Convertible Preferred Stock, value		-			-
Common stock to be issued, par value $0.001; 0 and 727,281 shares outstanding, respectively		—			727
Common Stock, par value $0.001; 300,000,000 shares authorized; 32,071,299 shares issued and outstanding		32,071			32,071
Additional paid-in capital		14,~~335~~339,~~776~~323			14,~~135~~339,~~257~~323
Accumulated deficit		(1516,~~701~~817,~~725~~238	)		(1516,~~117~~300,~~963~~075	)
Total Stockholders’ Deficit		(12,~~333~~445,~~878~~844	)		(~~950~~1,~~791~~928,681	)
Total Liabilities and Stockholders’ Deficit	$	~~208,486~~-		$	7239,~~021~~656

See accompanying notes to unaudited condensed consolidated financial statements.

VICAPSYS LIFE SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	2023			2022			2023			2022
	2024			2023			2024			2023
	For the three months ended September 30,						For the nine months ended September 30,
	For the three months ended June 30,						For the six months ended June 30,
	2023			2022			2023			2022
	2024			2023			2024			2023
Revenues	$	-		$	-		$	-		$	-
Operating Expenses:
Personnel costs		6962,~~181~~500			3066,~~470~~913			~~200,~~125,000			91130,~~754~~944
Research and development expenses, related party		310,~~267~~000			32,~~097~~000			1510,~~267~~344			1312,~~097~~000
Professional fees		76106,~~050~~500			9951,~~257~~467			~~240~~213,~~303~~048			~~346~~164,~~124~~253
General and administrative expenses		262,~~925~~841			1215,~~257~~313			6437,~~076~~705			4139,~~210~~773
Total operating expenses		~~175~~181,~~423~~841			~~145~~135,~~081~~693			~~519~~386,~~771~~097			~~492~~346,~~185~~970
Loss from operations		(~~175~~181,~~423~~841	)		(~~145~~135,~~081~~693	)		(~~519~~386,~~771~~097	)		(~~492~~346,~~185~~970	)
Other (Expenses):
Other Expenses:
Interest expense		(98,~~954~~250	)		—-			~~(10~~44,~~660~~767	)		—-
Financing costs		(54,963	)		—			(56,878	)		—
Loss on debt extinguishment		-			-			86,300			-
Total other expenses		~~(64~~8,~~917~~250	)		—-			~~(67~~131,~~538~~067	)		—-
Loss before income taxes		(240,340	)		(145,081	)		(587,309	)		(492,185	)
Income (loss) before income taxes		(190,091	)		(135,693	)		(517,164	)		(346,970	)
Income taxes		—-			—-			—-			—-
Net loss	$	(240,340	)	$	(145,081	)	$	(587,309	)	$	(492,185	)
Net income (loss) available to common shareholders	$	(190,091	)	$	(135,693	)	$	(517,164	)	$	(346,970	)
Deemed dividend on warrant modification		—			(3,548	)		—			(3,548	)
Net income (loss) per common share:
Net loss available to common stockholders	$	(240,340	)	$	(148,629	)	$	(587,309	)	$	(495,733	)
Basic and diluted	$	(0.01	)	$	(0.00	)	$	(0.02	)	$	(0.01	)
Net loss per common share:
Basic and diluted	$	(0.01	)	$	(0.00	)	$	(0.02	)	$	(0.02	)
Weighted average common shares outstanding:
Basic and diluted		34,~~405~~188,~~105~~461			3135,~~188~~314,~~461~~313			34,~~405~~188,~~105~~461			3035,~~372~~314,~~261~~313

See accompanying notes to unaudited condensed consolidated financial statements.

VICAPSYS LIFE SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

For the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2023~~2024 and ~~2022~~2023

(Unaudited)

	Shares		Amount		Shares			Amount			Capital			Deficit			(Deficit)
	Common Stock				Common Stock to be Issued						Additional Paid-in			Accumulated			Stockholders’Equity
	Shares		Amount		Shares			Amount			Capital			Deficit			(Deficit)
Balance December 31, 2021		19,747,283	$	19,747		12,067,458		$	12,068		$	13,976,159		$	(14,129,625	)	$	(121,651	)
Balance December 31, 2022		31,188,460	$	31,188		727,281		$	727		$	14,135,257		$	(15,117,963	)	$	(950,791	)
Common stock issued from common stock to be issued		11,441,177		11,441		(11,441,177	)		(11,441	)		—			—			—
Stock-based compensation expense		—		—		—			—			1,081			—			1,081
Net loss		—		—		—			—			—			(167,047	)		(167,047	)
Balance March 31, 2022		31,188,460		31,188		626,281			627			13,977,240			(14,296,672	)		(287,617	)
Stock-based compensation expense		—		—		—			—			1,081			—			1,081
Net loss		—		—		—			—			—			(180,056	)		(180,056	)
Balance June 30, 2022		31,188,460		31,188		626,281			627			13,978,321			(14,476,728	)		(466,592	)
Adjustment of expiration date on certain warrants		—		—		—			—			3,548			(3,548	)		—
Common stock issued from warrant exercise		—		—		100,000			100			49,900			—			50,000
Stock-based compensation expense		—		—		—			—			41,395			—			41,395
Net loss		—		—		—			—			—			—			(145,081	)
Balance Septmeber 30, 2022		31,188,460	$	31,188		726,281		$	727		$	14,073,164		$	(14,480,276	)	$	(520,278	)
Balance December 31, 2022		31,188,460		31,188		727,281			727			14,131,709			(15,117,963	)		(950,791	)
Stock-based compensation expense		—		—		—			—			20,697			—			20,697
Net loss		—		—		—			—			—			(211,277	)		(211,277	)
Balance March 31, 2023		31,188,460		31,188		727,281			727			14,~~152~~155,~~406~~954			(15,~~325~~329,~~692~~240	)		(1,~~144~~141,~~919~~371	)
Common stock to be issued pursuant to private placement completed in April 2023		—		—		400,000			400			99,600			—			100,000
Common stock to be issued per loan commitment		—		—		328,571			329			83,197			—			83,526
Net loss		—		—		—			—			—			(135,693	)		(135,693	)
Balance June 30, 2023		31,188,460	$	31,188		1,455,852		$	1,456		$	14,~~335~~338,~~203~~751		$	(15,~~461~~464,~~385~~933	)	$	(1,093,538	)
Common stock issued from common stock to be issued		882,839		883		(828,571	)		(829	)		(54	)		—			—
Balance December 31, 2023		32,071,299	$	32,071		—			—		$	14,339,323		$	(16,300,075	)	$	(1,928,681	)
Common stock cancelled from common stock to be issued		—		—		(627,281	)		(627	)		627			—			—
Net loss		—		—		—			—			—			(327,072	)		(327,072	)
Net loss		—		—		—			—			—			(240,340	)		(240,340	)
Balance March 31, 2024		32,071,299		32,071		—			—			14,339,323			(16,627,147	)		(2,255,753	)
Balance September 30, 2023		32,071,299	$	32,071		—		$	(0	)	$	14,335,776		$	(15,701,725	)	$	(1,333,878	)
Balance		32,071,299		32,071		—			—			14,339,323			(16,627,147	)		(2,255,753	)
Net loss		—		—		—			—			—			(190,091	)		(190,091	)
Balance June 30, 2024		32,071,299	$	32,071		—		$	—		$	14,339,323		$	(16,817,238	)	$	(2,445,844	)
Balance		32,071,299	$	32,071		—		$	—		$	14,339,323		$	(16,817,238	)	$	(2,445,844	)

See accompanying notes to unaudited condensed consolidated financial statements.

VICAPSYS LIFE SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	2023			2022
	2024			2023
	For the Nine Months Ended September 30,
	For the Six Months Ended June 30,
	2023			2022
	2024			2023
Cash Flows from Operating Activities:
Net loss	$	(587,309	)	$	(492,185	)
Net (loss)	$	(517,164	)	$	(346,970	)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net (loss) to net cash used in operating activities:
Amortization of intangible asset		—			23,468
Stock-based compensation		-			20,697
Stock-based compensation		20,697			43,557
Amortization of debt discount		27,844			1,393
Amortization of debt discount		63,639			—
Loss on debt extinguishment		86,300
Deferred offering costs		-			(18,649	)
Changes in operating assets and liabilities:
Prepaid Expenses		~~(44~~30,~~797~~234	)		(470,~~040~~297	)
Accounts payable		37174,~~996~~282			84158,~~116~~634
Accounts payable, related parties		~~174~~195,~~304~~248			~~103~~27,~~999~~132
Net Cash Used in Operating Activities		(~~335~~3,~~470~~256	)		(~~241~~228,~~085~~060	)
Cash Flows from Financing Activities:
Proceeds from exercise of warrants		—			50,000
Short-term note payable		(6,166	)		-
Proceeds from private placement		~~100,000~~-			—100,000
Proceeds from short-term note payable		~~36,789~~-			—54,230
Proceeds from short-term convertible note		290,349			—
Proceeds from convertible note		-			291,010
Deferred offering costs		(52,233	)		—
Net Cash (Used in) Provided by Financing Activities		(6,166	)		445,240
Net Cash Provided By Financing Activities		374,905			50,000
Net (decrease) increase in Cash		(9,422	)		217,180
Net increase (decrease) in Cash		39,435			(191,085	)
Cash, Beginning of period		9,422			14,097
Cash, Beginning of period		14,097			217,295
Cash, End of period	$	-		$	231,277
Cash, End of period	$	53,532		$	26,210
Supplementary Cash Flow Information
Cash paid for interest	$	~~10,660~~212		$	-706
Cash paid for taxes	$	~~456~~-		$	-545
Supplementary Non-Cash Flow Information
Non-cash investing and financing activities
Original issuance discount	$	83,526		$	-
Commitment Fee	$	-		$	83,526
Debt discount	$	26,400		$	-
Discount on debt	$	-		$	26,400

See accompanying notes to unaudited condensed consolidated financial statements.

VICAPSYS LIFE SCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION

Business

Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.

Per the schedule 14C filed on July 28, 2023, on July 28, 2023, stockholders of the Company approved a reverse split in the range from 1-for-2 to 1-for-50, with the Board of Directors able to pick the ratio or abandon the split. The split is subject to FINRA clearance and filing with Secretary of State. As of the date of this filing such split has not occurred.

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $~~587~~190,~~309~~091 and $517,164 for the ~~nine~~three and six months ended ~~September~~June 30, ~~2023~~2024, had a working capital deficit of $12,~~333~~445,~~878~~846 and an accumulated deficit of $1516,~~701~~817,~~725~~238 as of ~~September~~June 30, ~~2023~~2024. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business within one year after the date that the financial statements are issued. These unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might result from this uncertainty.

In ~~March~~ ~~2020~~July 2024, ~~the~~entered ~~World~~into ~~Health Organization declared the novel COVID-19 virus as~~ a ~~global~~promissory ~~pandemic.~~note ~~The~~agreement ~~COVID-19~~for ~~outbreak in~~ the ~~United States~~principal ~~continued~~amount ~~to negatively impact to the Company’s ability to secure additional debt or equity funding to support operations in 2022 and 2023. In 2022, the Company received proceeds~~ of $5095,000 ~~from the exercise of warrants~~. The InNote ~~April~~is ~~2023,~~convertible ~~the~~upon ~~Company raised~~ an ~~aggregate~~event of ~~$100,000~~default ~~from~~into ~~the sale of 400,000~~ shares of common stock, ~~to support current operations and extend research and development~~$0.001 ofpar ~~its~~value ~~product~~per ~~line~~share. WeIn ~~also~~August ~~secured a short-term convertible loan in June 2023 for $330~~2024,~~000~~ ~~which~~the ~~contained~~Company ~~separately~~entered aninto ~~original~~a ~~issuance discount~~promissory ofnote ~~$26,400.~~agreement ~~From~~for ~~this~~the ~~short-term~~principal ~~convertible~~sum ~~loan, we received net proceeds~~ of $~~290~~55,~~350~~000. The ~~short-term~~maturity ~~convertible~~date ~~loan~~on ~~was also~~the ~~issued~~promissory ~~with~~note ais ~~debt~~May 10, ~~discount~~2025 ofand ~~$83,526~~carries ~~that~~an ~~was~~annual ~~paid~~interest inrate ~~shares~~ of ~~common stock~~10%.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements in this report have been prepared by the Company without audit. In the opinion of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain information and note disclosures normally included in the Company’s consolidated annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted.

These unaudited consolidated financial statements should be read in conjunction with a reading of the Company’s consolidated audited financial statements and notes thereto for the year ended December 31, 2022, filed with the Company’s annual report on Form 10-K with the Securities and Exchange Commission (the “SEC”) on April 14, 2023. Interim results of operations for the three and nine months ended September 30, 2023, and 2022, are not necessarily indicative of future results for the full year. The unaudited consolidated financial statements of the Company include the consolidated accounts of VLS and its wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation.8

These unaudited consolidated financial statements should be read in conjunction with a reading of the Company’s consolidated audited financial statements and notes thereto for the year ended December 31, 2023, filed with the Company’s annual report on Form 10-K with the Securities and Exchange Commission (the “SEC”) on October 21, 2024. Interim results of operations for the three and six months ended June 30, 2024, and 2023, are not necessarily indicative of future results for the full year. The unaudited consolidated financial statements of the Company include the consolidated accounts of VLS and its wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates included in the financial statements, include useful the life of intangible assets, valuation allowance for deferred tax assets and non-cash equity transactions and stock-based compensation.

Cash

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. The Company held no cash equivalents as of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

Intangible Assets

Costs of intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the unaudited consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining patent life of the related patents being licensed.

In 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

Deferred Offering Costs

The Company capitalizes expenses incurred in connection with efforts to up list to a National Stock Exchange. The Company incurred $33,585 and $52,233 for the three and nine months ended September 30, 2023, respectively, in expenses related to up listing efforts. As of September 30, 2023 there was $102,674 in deferred offering costs recognized on the unaudited consolidated balance sheet. The Company did not incur any expenses for the three and nine months ended September 30, 2022 related to up listing efforts.

Long-Lived Assets

The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. In 2022, management reviewed the Company’s long-lived assets and concluded an impairment of the License Agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

Fair Value of Financial Instruments

ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of ~~September~~June 30, 2024 and December 31, 2023.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, and debt discounts approximate their fair values because of the short maturity of these instruments.

Revenue Recognition

Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company did not generate any revenue for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, and ~~2022~~2023.

Stock-Based Compensation

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,” which requires recognition in the financial statements of the cost of employee, director and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under the FASB’s Accounting Standards Update ASU 2016-09 Improvements to Employee Share-Based Payment.

Research and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. The Company incurred $310,~~267 and~~000 and $1510,~~267~~344 in research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, respectively, with a related party. The Company incurred $32,~~097~~000 and $1312,~~097~~000 in research development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023, respectively, with a related party.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure, and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

Earnings (Loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period using the treasury stock method and as-if converted method. As of ~~September~~June 30, ~~2023~~2024, and ~~2022~~2023, the Company’s dilutive securities are convertible into 3,~~000~~119,~~000~~300 and 34,~~396~~455,~~281~~852 shares of common stock, respectively, which are not included in the computation of dilutive loss per share because their impact is antidilutive.

The following table represents the classes of dilutive securities as of ~~September~~June 30, ~~2023~~2024, and ~~2022~~2023:

	September 30, 2023		September 30, 2022
	June 30, 2024		June 30, 2023
Common stock to be issued		—		~~726~~1,~~281~~455,852
Stock options		2,670,000		2,670,000
Convertible Debt		~~330~~449,~~000~~300		—330,000
Anti-dilutive securities		3,~~000~~119,~~000~~300		34,~~396~~455,~~281~~852

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, and ~~2022~~2023.

11NOTE 4 – RELATED PARTY TRANSACTIONS

NOTE 4 – INTANGIBLE ASSETS

The Company’s intangible assets consist of costs incurred in connection with the License Agreement with MGH (See Note 5). The consideration paid for the rights included in the License Agreement was in the form of common stock shares which resulted in MGH receiving approximately 20% of the total outstanding shares of common stock of VI. The estimated fair value of the common stock as of the date of the agreement is being amortized over the term of the License Agreement which is based on the remaining patent life of the related patents being licensed which is approximately 16 years.

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment (“ASC 360”) requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset is not recoverable based on the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset, and if the carrying amount exceeds the asset’s fair value. Per ASC 360, a long-lived asset should be tested for recoverability whenever events or changes in circumstances indicate that its’ carrying amount may not be recoverable. In 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment as of December 31, 2022 by evaluating whether the anticipated future benefit and estimated undiscounted cashflows of the license agreement exceeded the carrying value of the intangible asset of approximately $348,000 as of that date.

The Company concluded an impairment of the license agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset. As such, the Company wrote off the carrying value of the asset as of December 31, 2022.

The Company did not incur any amortization expense related to the License Agreement for the three and nine months ended September 30, 2023. The Company recognized $7,822 and $23,468 of amortization expense related to the License Agreement with MGH for the three and nine months ended September 30, 2022 which is included in general and administrative expenses on the unaudited consolidated statements of operations.

NOTE 5 – RELATED PARTY TRANSACTIONS

Consulting Agreements

On November 5, 2021, the Company entered into a Consulting Agreement (the “Poznansky Agreement”) with Mark Poznansky, MD, a minority stockholder and former Director. The Company engaged Dr. Poznansky to render consulting services with respect to informing, guiding, and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Poznansky Agreement was for six months (the “Initial Term”), which was extended indefinitely, and the Company agreed to pay the Consultant $2,000 per month commencing November 5, 2021, with consideration for an increase in the monthly fee following the completion for the Company’s successful up listing to the NASDAQ Stock Market. The Company incurred a total of $6,000 and $1812,000, respectively, in expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024 and ~~2022~~2023, ~~respectively,~~ related to the Poznansky Agreement, which is included in professional fees on the unaudited consolidated statements of operations. As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $3553,500 and $2635,~~000~~500, respectively, is included in accounts payable, related parties, on the unaudited consolidated balance sheets, related to the Poznansky Agreement.

MGH License Agreement

On May 8, 2013, VI and MGH, a principal stockholder (see Note 65), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”).

As amended by the Ninth Amendment to the License Agreement on May 30, 2023 (“Effective Date”), which adds to the due diligence requirements as amended by Eighth Amendment to the License Agreement, requires that within one year of the Ninth Amendment Effective Date, the Company shall submit a research and development plan for the patent rights associated with MGH 24644 with mutually acceptable diligence requirements to be added by amendment to the Agreement for development of the product or process for the therapy and/ or prophylaxis of a human disorder in the license field.

As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates.

Pre-Sales Diligence Requirement:

	(x)	The Company shall provide a detailed business plan and development plan by June 1st, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.
	(xi)	The Company shall raise $2 million in financing by December 1st, 2022. As of the date of this filing the Company has yet to raise $2 million and is negotiating the extension of this requirement with MGH.
	(xii)	The Company shall raise an additional $8 million in financing by December 1st, 2023.
	(xiii)	The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1st, 2023.
	(xiv)	The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1st, 2023.
	(xv)	The Company shall initiate research regarding other applications of the CXCL12 platform by June 1st, 2023. As of the date of this filing the Company has yet to initiate research regarding other applications of the CXCL12 platform and is negotiating the extension of this requirement with MGH..
	(xvi)	The Company shall initiate a Phase I clinical trial of a Product or Process by March 1st, 2024.
	(xvii)	The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.
	(xviii)	The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.

	(x)	The Company shall provide a detailed business plan and development plan by June 1^st, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.
	(xi)	The Company shall raise $2 million in financing by December 1^st, 2022. As of the date of this filing the Company has yet to raise $2 million and is negotiating the extension of this requirement with MGH.
	(xii)	The Company shall raise an additional $8 million in financing by December 1^st, 2023. As of the date of this filing the Company has yet to raise $8 million and is negotiating the extension of this requirement with MGH.

	(xiii)	The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1^st, 2023.
	(xiv)	The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1^st, 2023.
	(xv)	The Company shall initiate research regarding other applications of the CXCL12 platform by June 1^st, 2023. As of the date of this filing the Company has yet to initiate research regarding other applications of the CXCL12 platform and is negotiating the extension of this requirement with MGH..
	(xvi)	The Company shall initiate a Phase I clinical trial of a Product or Process by March 1^st, 2024.
	(xvii)	The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.
	(xviii)	The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.

Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates.

Post-Sales Diligence Requirements:

	(i)	The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan.

	(ii)	Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company.

In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments:

	(i)	Prior to the First Commercial Sale, the Company shall pay to MGH a non-refundable annual license fee of ten thousand dollars ($10,000) by June 30, 2022, and on each subsequent anniversary of the Eighth Amendment Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. As of ~~September~~June 30, ~~2023~~2024, the Company has yet to pay the second non-refundable license fee and is included in accounts payable, related party, on the unaudited consolidated balance sheets.
	(ii)	Following the First Commercial Sale, Company shall pay MGH a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($100,000) per year within sixty (60) days after each annual anniversary of the Effective Date. The annual minimum royalty shall be credited against royalties subsequently due on Net Sales made during the same calendar year, if any, but shall not be credited against royalties due on Net Sales made in any other year.

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes (“T1D”). Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement.

The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH.

VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes.

The Company incurred costs to MGH of $~~3,267~~ 0 and $1510,~~267~~ 344 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, respectively, which is classified as research and development costs, related party, on the consolidated unaudited statements of operations. The Company incurred costs to MGH of $32,~~097~~ 000 and $1312,~~097, respectively,~~ 000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 which is classified as research and development costs, related party, on the consolidated unaudited statements of operations. As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $1828,~~364~~708 and $315,097, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, for services that remain unpaid.

14During the three and six months ended June 30, 2024, and 2023, there have not been any sales of Product or Process under this License Agreement.

During the three and nine months ended September 30, 2023, and 2022, there have not been any sales of Product or Process under this License Agreement.

Accounts Payable, related parties and Accrued Salaries, related party

The Company incurred director fees of $62,500 and $~~187~~125,~~500, respectively,~~ 000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~respectively, to Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board, which are included in personnel costs on the unaudited consolidated statements of operations. The Company incurred director fees of $3062,~~000~~ 500 and $90125,000, respectively, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022,~~ ~~respectively, to Mr~~2023. ~~Pier.~~ As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $~~248~~437,~~058~~ 379 and $~~144~~310,~~000~~558, respectively, of these director fees are included in accounts payable, related parties, on the unaudited consolidated balance sheets.

The Company incurred consulting fees of $22,500 and $6745,~~500~~000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024 and ~~2022~~2023, respectively, to Jeff Wright, the Company’s Chief Financial Officer, which are included in professional fees on the unaudited consolidated statements of operations. As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $~~135~~204,~~700~~110 and $99158,~~000,~~027 respectively, is included in accounts payable, ~~related~~ related parties, on the unaudited consolidated balance sheets.

In August 2020, Frances Tonneguzzo, the Company’s Chief Executive Officer (the “former CEO”) tendered her resignation as CEO. For the three and ~~nine~~six months ended ~~September~~June 30 ~~2023~~, 2024 and ~~2022~~2023, the Company did not incur any expenses to the former CEO. As of ~~September~~ June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $115,312, respectively, of unpaid salary to the former CEO is included in accrued salaries, ~~related~~ related party on the unaudited consolidated balance sheets. See Note 65 for a consulting agreement executed with the former CEO.

NOTE 65 – COMMITMENTS AND CONTINGENCIES

Legal Matters

The Company is not aware of any material, existing or pending legal proceedings against the Company, nor is it involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

MGH License Agreement

As discussed in Note 54, the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. As of ~~September~~June 30, ~~2023~~2024, the Company had yet to pay the second non-refundable license fee and is included in accounts payable, related party, on the unaudited consolidated balance sheet. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual ~~minimum~~ minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date. The Company has yet to generate any revenue as of ~~September~~June 30, ~~2023~~2024.

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of T1D. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. No$0 and $344 of expense reimbursements were paid to MGH during the three and ~~nine~~six months ended ~~September~~June 30, ~~2023,~~2024. No expense reimbursements were paid to MGH during the three and ~~2022~~six months ended June 30, 2023. As of ~~September~~ June 30, ~~2023~~2024, ~~and~~$28,708 is included in accounts payable, related parties, on the unaudited consolidated balance sheet. As of December 31, ~~2022~~2023, $18,364 ~~and $3,097, respectively,~~ is included in accounts payable, related parties, on the ~~unaudited~~ consolidated balance ~~sheets~~sheet.

Consulting Agreements

On January 12, 2022, the Company entered into a Consulting Agreement (the “Donohoe Agreement”) with Donohoe Advisory Associates, LLC. (the “Consultant”). The Company engaged the Consultant to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company agreed to pay the Consultant a retainer fee of $17,500, which is to be applied to the Company’s monthly invoices until such time as the retainer fee is exhausted or the ~~engagement~~ engagement under the agreement ends. The Company ~~incurred~~did ~~$6,820~~not inincur any expenses related to the Donohoe Agreement for the three and ~~nine~~six months ended June ~~September~~ 30, ~~2023~~2024 ~~related to~~and ~~the Donohoe Agreement~~2023. ~~The~~As ~~Company~~of ~~incurred~~June ~~$0 and $10~~30,~~680~~ in2024 ~~expenses for the three~~ and ~~nine~~December ~~months ended September 30~~31, ~~2022~~2023, ~~respectively, which~~the ~~are~~balance ~~included~~owed inrelated ~~professional~~to ~~fees on~~ the ~~unaudited~~Donohoe ~~consolidated~~Agreement ~~statements~~was ~~of operations~~$1, 755 and ~~none of which~~ is included in accounts payable on the ~~unaudited~~ consolidated balance ~~sheet~~sheets.. If the Company is successful in listing on an exchange, the Company will be obligated to pay a “success fee” to the Consultant of either $10,000 or that number of registered common shares equivalent to $10,000 divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the ~~success~~ success fee will be determined by the Company.

On March 7, 2022, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Alpha IR Group, LLC. (the “Consultant”). The Company engaged the Consultant to provide consulting, investor relations, and corporate and ~~transaction~~ transaction communication related services. The initial term of the Consulting Agreement was for three months (the “Initial Term”) beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $50,000 payable in cash or stock options for the three months of service. The Company did not incur any expenses related to the Consulting agreement for the three and six months ended June 30, 2024. The Company incurred $0 and $24,000, respectively, in expenses for the three and ~~nine~~six months ended ~~September~~June 30, 2023, which are included in professional fees on the unaudited consolidated statements of operations. ~~The~~As ~~Company~~of ~~incurred~~June ~~$0 and $50~~30,~~000~~ ~~in expenses~~2024 ~~for the three~~ and ~~nine~~December ~~months ended September 30~~31, ~~2022. As of September 30,~~ 2023, the balance owed related to the ~~Consultant~~Consulting Agreement was $7473,~~000~~999 ~~which~~and is included in accounts payable on the unaudited consolidated balance sheet.

Employment Agreement

The Company has an employment agreement with Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board. Pursuant to the terms of the employment agreement, Mr. Pier will receive a $100,000 one-time cash bonus if the Company’s common stock is up listed to NASDAQ or the New York Stock Exchange, or the Company secures and receives financing of at least $8 million. Additionally, the Company shall issue Mr. Pier, pursuant to the Company’s equity incentive plan, a restricted stock unit award containing the following terms: Mr. Pier shall receive shares of common stock of the Company (i) representing 1% of the Company’s fully diluted equity as of the payment date (the “Initial Equity Payment”) if the Company achieves a market capitalization of at least $250 million for sixty consecutive days during the Term (the “Initial Market Capitalization Target”); and (ii) representing the difference between 2% of the Company’s fully diluted equity as of the payment date and the amount of Initial Equity Payment (the “Subsequent Equity Payment” and, together with Initial Equity Payment, “Equity Payments”) if the Company achieves a market capitalization of at least $500 million for sixty consecutive days during the Term (the “Subsequent Market Capitalization Target” and, together with Initial Market Capitalization Target, “Market Capitalization Targets”), such that Mr. Pier has, in the aggregate, received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the date of payment of Subsequent Equity Payment. The Company will use issue such Equity Payments within seventy-three days after the attainment of the applicable Market Capitalization Target. Mr. Pier shall remain eligible to receive additional equity-based compensation awards as the Company may grant from time to time.

On January 1, 2022, the Company entered into a consulting agreement (the “Toneguzzo Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Toneguzzo Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant received $5,000 per month. The Company did not extend the Toneguzzo Agreement after the expiration of the one-year term. As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, $40,000 is included in accounts payable on ~~the~~ the unaudited consolidated balance sheets, related to the Toneguzzo Agreement.

16NOTE 6 – SHORT-TERM LIABILITIES

NOTE 7 – SHORT-TERM LIABILITIES

Convertible Note Payable

As discussed in Note 2, on June 27, 2023, the Board of Directors approved a resolution authorizing the Company to obtain a secured six-month term loan for the principal amount of $330,000. In connection therewith, on June 27, 2023, the Company entered into a Securities Purchase Agreement with selected accredited investors whereby the Company had the right to secure the convertible note. The holder has conversion rights upon event of default and the conversion price is equal to the average of the three lowest prices of the Company’s common stock of the trailing ten days prior to the date conversion of the convertible note. At issuance and at ~~September~~June 30, ~~2023~~2024, the Company ~~estimated~~ estimated the fair value of the conversion option embedded in the Note and determined its value to be de minimis due to the fact that ~~settlement~~ settlement into shares of common stock only occurs upon an event of default. If the event of default were triggered this would provide the Note holder with little upside potential and therefore no value was allocated to the embedded derivative.

Original Issuance Discount

The principal face value of the loan is $330,000 and was issued with an original issuance discount of $26,400 which resulted in aggregate proceeds of $303,600. The loan carries an interest rate of 10% per year, has a default interest rate of 18% per year, and a maturity date of December 27, 2023. Interest is payable on a monthly basis beginning one month following the issue date. Following an event of default, the noteholder has the right to convert all or any part of the outstanding and unpaid principal, interest, penalties, and all other amounts under the note into fully paid and non-assessable shares of Common Stock. Additionally, the noteholders have the option to convert the $26,400 original issuance discount, which will accrete over the life of the loan based on the effective interest method. The convertible note is also presented net of the issuance costs of $13,250 which will accrete over the life of the note, based on the effective interest method. ~~Accretion~~The ~~expense~~Company ~~incurred~~did not incur any accretion expense related to the original issuance discount for the three and six ~~nine~~ months ended ~~September~~ June 30, ~~2023 was approximately $19~~2024,~~825~~ and ~~$20,486, respectively~~2023.

Debt Discount

To secure the convertible note, the Company paid a commitment fee of $83,526 by issuing 328,571 shares of the Company’s common stock. See Note 8. The convertible note is also presented net of the debt discount of $83,526 which represents the relative fair value of the common stock issued, which was fully recognized as of ~~September~~December 3031, 2023,. ~~which~~The ~~will~~company ~~accrete~~did ~~over~~not ~~the~~incur ~~life~~any ofaccretion ~~the convertible note. Accretion~~ expense ~~incurred~~ related to the debt discount for the three ~~and nine~~ months ended ~~September~~June 30, ~~2023 was approximately $41~~2024,~~763~~ and ~~$43,153, respectively~~2023.

~~The~~Debt ~~balance of the convertible note as of September 30, 2023 was $270,465, which is presented net of aggregate debt discount of $206,824 and aggregate accretion expense of $63,639.~~Amendments

On December 26, 2023, the Company and the note holder entered into a letter agreement under which an agreement was made to extend the maturity date of the Note to January 27, 2024, increase the principal of the note to $363,000, and amend the convertible note to extend the date on which the Company shall prepare and file with the SEC a registration statement covering the resale of all of the conversion shares and commitment fee to January 27, 2024. The Company subsequently failed to repay the convertible note on or before January 27, 2024, and failed to file the resale registration statement on or before January 27, 2024. The amendment was deemed a debt modification and a total of $33,000 was recognized as inducement expense.

On February 6, 2024, the Company and convertible note holder entered into a letter agreement under which an agreement was made to extend the maturity date of the note to February 27, 2024, increase the principal of the convertible note to $399,300, extend the date on which the Company shall prepare and file the resale registration statement with the SEC to February 27, 2024, and extend the registration effective date for the resale registration statement until April 27, 2024.

On March 26, 2024, the Company and the note holders entered into a letter agreement under which an agreement was made to extend the maturity date of the note to April 27, 2024, and increase the principal of the note to $449,300. As a result of the debt modification, the Company recognized $0 and $50,000 of loss on debt extinguishment for the three and six months ended June 30, 2024, respectively.

In April 2024, the note holders agreed to extend the maturity date of the convertible note to October 31, 2024, and any accrued but unpaid interest through the date thereof shall be due and payable on or before October 31, 2024. The extension did not have any modification or extinguishment consideration.

As of the date of this filing, the Company subsequently failed to repay the convertible note on or before October 31, 2024, and failed to file the resale registration statement on or before October 31, 2024. In December 2024, the note holder agreed to and issued a one-time waiver applicable to the default and failure to comply with the purchase agreement debt modifications through December 31, 2024.

Short-Term Note Payable

The Company entered into a commercial insurance premium finance and security agreement in May 2023. The agreement finances the Company’s annual D&O insurance premium. Payments are due in monthly installments of approximately $6,400 and carry an annual percentage interest rate of 13.9%.

The Company had an outstanding premium balance of approximately $3612,~~789~~546 and $18,712 at ~~September~~June 30, 2024 and December 31, 2023, respectively, related to the agreement, which is included in short-term note payable in the consolidated balance sheets. Interest expense incurred for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~ 2024, related to the finance agreement was approximately $~~1,694~~ 0 and $2635,~~400,~~ respectively.

17As of the date of this filing the Company is in default of the commercial premium finance agreement and the D&O insurance policy is no longer in effect.

~~NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT)~~16

NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT)

Preferred Stock

The Company has 207,~~000~~440,000 authorized shares of preferred stock, $0.~~001~~0001 par value per share.

Series A Preferred Stock

On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $0.001 par value per share, consisting of 3 million (3,000,000) shares. Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series A Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Certificate of Designation or under applicable law.

In the event of liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of (i) the sum of $1.67 per share or (ii) such amount per share as would have been payable had all shares been converted to common stock.

Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into 6,000,000 shares of common stock to be issued on February 12, 2021, (the one-year anniversary of the initial filing by the Company of the Form 10 filed with the SEC). The common stock shares for the conversion of the Series A Preferred Stock were issued on January 13, 2022.

As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, there were -0- shares of Series A Preferred Stock issued and outstanding.

Series B Preferred Stock

On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $0.~~001~~0001 par value per share, consisting of 4.44 million (4,440,000) shares (the “Series B Preferred Stock Certificate of Designation”).

Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series B Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Series B Preferred Stock Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of : the sum of $0.83 per share or such amount per share as would have been payable had all shares been converted to common stock.

The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

18As of June 30, 2024, and December 31, 2023, there were -0- shares of Series B Preferred Stock issued and outstanding.

Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into 4,440,000 shares of common stock to be issued on February 12, 2021, the one-year anniversary of the initial filing by the Company of the Form 10 filed by the Company with the SEC. The common stock shares for the conversion of the Series B Preferred Stock were issued on January 13, 2022.17

As of September 30, 2023, and December 31, 2022, there were -0- shares of Series B Preferred Stock issued and outstanding.

Common Stock

The Company has 300,000,000 authorized shares of common stock, $0.001 par value per share. As of ~~September~~June 30, ~~2023~~2024, and December 31, ~~2022~~2023, ~~there~~ there were 32,071,299 ~~and 31,188,460~~ shares, ~~respectively,~~ of common stock issued and outstanding.

Common Stock Issuances

OnIn ~~February~~connection ~~12,~~with ~~2021,~~ the ~~Company~~promissory ~~issued~~note ~~6,000,000~~as ~~shares~~discussed ofin ~~common~~Note ~~stock to the holders of Series A Preferred Stock~~6, ~~pursuant~~ to ~~the~~secure ~~automatic conversion feature of~~ the ~~Series A Certificate of Designation~~note, ~~whereby,~~ the ~~Series~~Company Apaid ~~shares~~a ~~are~~commitment tofee ~~automatically~~by ~~convert~~issuing ~~on the one-year~~328,571 ~~anniversary~~shares of the Company’s ~~filing~~common ~~its Registration Statement on Form 10~~stock. The ~~Form~~relative 10fair ~~Registration~~value ~~Statement~~of ~~was filed with~~ the ~~SEC on February 12, 2020. The~~ common stock ~~shares~~was ~~for~~$83,526 ~~the~~as ~~conversion~~ of ~~the~~June ~~Series~~30, A2023. ~~Preferred~~The ~~Stock~~shares were issued onin ~~January~~July ~~13, 2022~~2023.

On February 12, 2021, the Company issued 4,440,000 shares of common stock to the holders of Series B Preferred Stock, pursuant to the automatic conversion feature of the Series B Certificate of Designation, whereby, the Series B shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series B Preferred Stock were issued on January 13, 2022.

In 2022, the Company determined that the former Series B Preferred Stockholders, subsequent to all Series B Preferred Stock having previously been converted to shares of common stock in 2021, were owed additional shares of common stock due to an adjustment to the conversion price that occurred as a result of a down round trigger event that occurred in 2019 when the Company sold shares of common stock and a warrant in a private placement at a price of $0.25, which was below the original conversion ratio of the Series B Preferred Stock. Management determined the total additional shares owed to the Preferred B Stockholders to be 1,001,177 as a result of the down round trigger. The financial statement impact of this down round trigger was not significant. The shares owed to the Series B Preferred Stockholders due to the 2019 trigger event have been presented on the statement of stockholders’ deficit retrospectively as common stock to be issued with no impact on total stockholders’ deficit. The Company issued the additional shares to the Series B Preferred Stockholders on March 24, 2022.

In July 2022, the Company received proceeds totaling $50,000 and issued 100,000 shares of common stock pursuant to the exercise of warrants at $0.50 per share.

In connection with the promissory note as discussed in Note 7, to secure the note, the Company paid a commitment fee by issuing 328,571 shares of the Company’s common stock. The relative fair value of the common stock was $83,526 as of June 30, 2023. The shares were issued in July 2023.

In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering. The Company raised an aggregate amount of $100,000 issuing 400,000 shares of common stock at $0.25 per share. The shares were issued in July 2023.

Common Stock to be issued

As of September 30, 2023 and December 31, 2022, there were 0 and 727,281, respectively, shares of common stock to be issued.

As of December 31, 2022, there were 597,281 shares to be issued pursuant to a Stock Issuance and Release Agreement (“SRI Agreement”) executed by the Company in February 2019 to stockholders for no consideration who purchased shares in 2018 at $1.85, and 30,000 shares of common stock to be issued to two initial shareholders of VI. The issuance of these shares to be issued pursuant to the SRI Agreement and to the two initial shareholders of VI were cancelled as of September 30, 2023 due to the shareholders having never signed the agreement. Additionally, as of September 30, 2023 the Company recognized as issued 54,267 shares erroneously issued by the Company’s transfer agent back in 2018 related to a private offering as the Company does not expect the shares to be returned by shareholder. The remaining number of shares to be issued as of December 31, 2022 related to 100,000 shares to be issued pursuant to the exercise of warrants in July 2022.

Stock Option-Based Compensation Plan

On August 10, 2022, the Board of Directors of the Company approved and adopted the Vicapsys Life Sciences, Inc., 2022 Omnibus Equity Incentive Plan (the “Plan”). The material terms of the 2022 Plan are set forth below:

●	The Board or a committee established by the Board will administer the 2022 Plan.
●	The total number of shares of common stock authorized for issuance under the 2022 Plan is 3,200,000 shares of Common Stock plus, to the extent the Company issues new shares of Common Stock other than under the terms of the 2022 Plan or other than certain Inducement Awards, 3.1% of the shares of Common Stock issued by the Company in such issuance (or such lower amount as determined by the Board). As of August 16, 2022, 3,200,000 shares of Common Stock represents approximately 10.1% of our common stock outstanding.
●	Eligible recipients of awards include an employee, director or independent contractor of the Company who has been selected as an eligible participant by the Administrator, subject to certain limitations relating to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).
●	No non-employee director may be granted awards under the 2022 plan during any calendar year if such awards and cash fees paid for serving as a non-employee director would exceed $150,000 in the non-employee director’s initial year of service, or $195,000 in any year thereafter.
●	In no event shall the exercise price of an option issued pursuant to the 2022 Plan be less than one hundred percent (100%) of the Fair Market Value of a share of Common Stock on the date of grant.

The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and success of the Company, (ii) strengthen the commitment of such individuals to the Company and its Affiliates, (iii) motivate those individuals to faithfully and diligently perform their responsibilities and (iv) attract and retain competent and dedicated individuals whose efforts will result in the long-term growth and profitability of the Company. To accomplish these purposes, the Plan provides that the Company may grant Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Other Stock-Based Awards or any combination of the foregoing.

Stock Option Activity

The following table summarizes activities related to stock options of the Company for the ~~nine~~six months ended ~~September~~June 30, 2024 and 2023:

SCHEDULE OF STOCK OPTIONS ACTIVITY

	Number of Options		Weighted- Average Exercise Price per Share		Weighted- Average Remaining Life (Years)		Aggregate Intrinsic Value (Per Option)
Outstanding at December 31, 2022		2,670,000	$	0.62		6.21	$	—
Outstanding at September 30, 2023		2,670,000	$	0.62		5.46	$	—
Outstanding at June 30, 2023		2,670,000	$	0.62		5.71	$	—
Exercisable at September 30, 2023		2,670,000	$	0.62		5.46	$	—
Exercisable at June 30, 2023		2,670,000	$	0.62		5.71	$	—

The Company did not grant any options to purchase shares of common stock during the three and nine months ended September 30, 2023. As of September 30, 2023, there were 2,670,000 shares of fully vested stock options. The Company recorded stock compensation expense of $0 and $20,697, respectively, for the three and nine months ended September 30, 2023. The Company recorded stock compensation expense of $41,395 and $43,557 for the three and nine months ended September 30, 2022, respectively.

	Number of Options		Weighted- Average Exercise Price per Share		Weighted- Average Remaining Life (Years)		Aggregate Intrinsic Value (Per Option)
Outstanding at December 31, 2023		2,670,000	$	0.62		5.46	$	—
Outstanding at June 30, 2024		2,670,000	$	0.62		4.71	$	—
Exercisable at June 30, 2024		2,670,000	$	0.62		4.96	$	—

The Company did not grant any options to purchase shares of common stock during the three months ended June 30, 2024. As of June 30, 2024, there were 2,670,000 shares of fully vested stock options. The Company did not incur any stock compensation expense for the three and six months ended June 30, 2024. The Company recorded stock compensation expense of $0 and $20,697, respectively, for the three and six months ended June 30, 2023.

NOTE 8 – SUBSEQUENT EVENTS

In July 2024, the Board of Directors approved a resolution authorizing the Company to obtain a secured six-month term loan for the principal amount of $95,000. In connection therewith, on July 17, 2024, the Company entered into a Securities Purchase Agreement with selected accredited investors whereby the Company had the right to secure the convertible note. In connection with the convertible promissory note, to secure the note, the Company paid a commitment fee by issuing 300,000 shares of the Company’s common stock. The shares were issued in August 2024.

In July 2024, entered into a promissory note agreement for the principal amount of $95,000. The Note is convertible upon an event of default into shares of common stock, $0.001 par value per share.

In August 2024, the Company entered into a promissory note agreement for the principal sum of $55,000. The maturity date on the promissory note is May 10, 2025, and carries an annual interest rate of 10%.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto appearing in Part I, Item 1 of this Quarterly Report. Historical results and trends that might appear in this Quarterly Report should not be interpreted as being indicative of future operations.

Overview

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immuno protection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Results of Operations – Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2023,~~2024 and ~~2022~~2023

Revenues

The Company did not have any revenues for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024 and ~~2022~~2023.

Operating Expenses

We classify our operating expenses into four categories: personnel costs, research and development expenses, professional fees, and general and administrative expenses. The Company’s total operating expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, were $~~240~~181,~~340~~ 841 and $~~587~~386,~~309~~097, respectively, compared to $~~145~~135,~~081~~693 and $~~492~~346,~~185~~970 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023.

~~$10,833~~Personnel ~~monthly~~costs ~~increase~~remained inconsistent ~~Director~~at ~~fees for our CEO commencing in January 2023, resulted in an increase in personnel costs to~~ $6962,~~181~~500 and $~~200,~~125 ,000, respectively, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, ~~respectively,~~compared ~~from~~to $3066,~~470~~ 913 and $91130,~~754~~944, respectively, for the three and ~~nine~~six months ended ~~September~~ June 30, ~~2022~~2023. We incurred $310,~~267~~000 and $1510,~~267~~344 in research and development expenses during the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, respectively, related to a ninth amendment license fee and also an annual royalty fee we agreed to pay upon execution of the Eighth Amendment to the License Agreement with MGH. ~~Research~~We ~~and~~incurred ~~development~~$2,000 ~~expenses~~and ~~remained~~$12,000 ~~consistently~~in ~~low~~research and asdevelopment ~~the~~expenses ~~Company~~during ~~continued ongoing financing efforts in~~ the ~~wake~~three ofand ~~the~~six ~~negative~~months ~~impact~~ended ofJune ~~COVID-19~~30, ~~which~~2023, ~~continued~~respectively. toResearch ~~hinder~~and ~~the~~development ~~Company’s~~expenses ~~ability~~remained consistently tolow ~~raise~~as the ~~additional capital~~Company ~~necessary~~continued toongoing ~~maintain~~financing ~~regular operating activities~~efforts. The ~~increase~~decrease in general and administrative costs to $262,~~925~~841 and $6437,~~076 for~~705 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, respectively, from $1215,~~257~~313 and $4139,~~210~~773 for the three and ~~nine~~six months ended ~~September~~ June 30, ~~2022~~ 2023, respectively, was primarily due ~~insurance~~to ~~expense~~the ~~incurred~~cancellation ~~related~~of to the ~~new~~ D&O insurance policy in March 2024. The ~~decrease~~overall increase in professional fees toof $76106,~~050~~500 and $~~240~~213,~~303~~046 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2023~~2024, from $9951,~~257~~467 and $~~346~~164,~~124~~253 for the three and ~~nine months~~six months ended ~~September~~June 30, ~~2022~~2023, was primarily attributable to ~~the legal, accounting, and~~ consulting ~~and investor relations~~ costs incurred in ~~2022~~ in ~~support of the Company’s efforts to obtain a listing on a national securities exchange~~2024.

Funding Requirements

We anticipate that substantial additional equity or debt financings or funding from collaborative agreements or from foundations, government grants or other sources, will be needed to complete preclinical and animal testing necessary to file an Investigational New Drug Application with the U.S. Food and Drug Administration, and that further funding beyond such amounts will be required to commence trials and other activities necessary to begin the process of development and regulatory approval of a product for the continued growth of the Company. Additional capital will also be required for the clinical development of the recently discovered anti-fibrotic applications and corporate partnerships will be necessary to move Company products into advanced clinical development and commercialization. We also anticipate our cash expenditures will increase as we continue to operate as a publicly traded entity.

Additional capital will also be required for the clinical development of the recently discovered anti-fibrotic applications and corporate partnerships will be necessary to move Company products into advanced clinical development and commercialization. We also anticipate our cash expenditures will increase as we continue to operate as a publicly traded entity.

Liquidity and Capital Resources

At ~~September~~June 30, ~~2023~~2024, we had ~~$53,532~~a ofnegative cash onbalance ~~hand~~of $86 and an accumulated deficit of $1516,~~701~~807,~~725~~238.

We do not believe that we have enough cash on hand to operate our business during the next 12 months. We anticipate we will need to raise an additional $1 million through the issuance of debt or equity securities to sustain base operations during the next 12 months, excluding development work. There can be no assurance that we will be able to obtain additional funding on commercially reasonable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends.

If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, products or therapeutic candidates or to grant licenses on terms that may not be favorable to us.

To date, we have financed our operations through our sale of equity and debt securities. Failure to generate revenue or to raise funds could cause us to go out of business, which would result in the complete loss for investors in our Company.

To date, we have generated no revenues, and no substantial revenues are anticipated until we have implemented our full plan of operations. To implement our strategy to grow and expand per our business plan, we intend to generate working capital via a private placement of equity or debt securities, or to secure a loan. If we are unsuccessful in raising capital or securing a loan, we could be required to cease business operations and investors would lose all of their investment.

In July 2022, the Company received aggregate proceeds totaling $50,000 and issued 100,000 shares of common stock pursuant to the exercise of warrants at $0.50 per share.

In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $300,000 through the sale of shares of common stock at $0.25 per share. The Company has raised an aggregate amount of $100,000 as of the date of these consolidated financial statements.

In June 2023, the Board of Directors approved a resolution authorizing the Company to obtain a six-month term loan for the principal amount of $330,000. In connection therewith, the Company entered into a Securities Purchase Agreement with selected accredited investors whereby the Company secured a convertible promissory note in the amount of $330,000, which was issued with an original issuance discount of $26,400 and resulted in aggregate proceeds of $303,600. The Company received aggregate proceeds of $290,350, net of issuance costs.

In July 2024, entered into a promissory note agreement for the principal amount of $95,000. The Note is convertible upon an event of default into shares of common stock, $0.001 par value per share.

In August 2024, the Company entered into a promissory note agreement for the principal sum of $55,000. The maturity date on the promissory note is May 10, 2025 and carries an annual interest rate of 10%.

Additionally, we will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. Our management will have to spend additional time on policies and procedures to make sure our Company is compliant with various regulatory requirements.

This additional corporate governance time required of management could limit the amount of time management has to implement our business plan and may impede the speed of our operations.

Working Capital Deficit

	September 30, 2023			December 31, 2022
	June 30, 2024			December 31, 2023
Current Assets	$	~~208,486~~-		$	7239,~~021~~656
Current Liabilities		12,~~542~~435,~~364~~846			1,~~022~~968,~~812~~337
Working Capital Deficit	$	(12,~~333~~435,~~878~~846	)	$	(~~950~~1,~~791~~928,681	)

Cash Flows

Cash activity for the ~~nine~~six months ended ~~September~~June 30, ~~2023,~~2024 and ~~2022~~2023 is summarized as follows:

	Nine Months Ended September 30,
	Six Months Ended June 30,
	2023			2022
	2024			2023
Net cash used in operating activities	$	(~~335~~3,~~470~~256	)	$	(~~241~~228,~~085~~060	)
Net cash provided by financing activities		374,905			50,000
Net cash (used in) provided by financing activities		(6,166	)		445,240
Net increase (decrease) in cash	$	39,435		$	(191,085	)
Net (decrease) increase in cash	$	(9,422	)	$	217,180

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4) during the periods presented, investments in special-purpose entities or undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.

Contractual Obligations

MGH License Agreement

The Company has executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date.

As of the date of this filing the Company is in default of the pre-sales diligence requirements and is negotiating the extension of the requirements outlined in the License Agreement with MGH.

Consulting Agreement

The Company entered into a consulting agreement with Donohoe Advisory Associates, LLC to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company will be obligated to pay a “success fee” to the Consultant of either $10,000 or that number of registered common shares equivalent to $10,000 divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the success fee will be determined by the Company.

2321

Employment Agreement

The Company entered into a consulting agreement with Alpha IR Group, LLC to provide consulting, investor relations, and corporate and transaction communication related services. The initial term of the consulting agreement was for three months beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $50,000 payable in cash or stock options for the three months of service.

Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. We evaluate, on an ongoing basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our consolidated financial statements. The Securities and Exchange Commission (the “SEC”), considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation.

We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our interim consolidated financial statements.

Our significant accounting policies are described in more detail in the notes to our consolidated financial statements for the fiscal year ended December 31, ~~2022~~2023, included in the Company’s Annual Report filed on Form 10-K with the SEC on ~~April~~October 1421, ~~2023~~2024.

Recent Accounting Pronouncements

2422

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

In designing and evaluating the Company’s disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired objectives, and the Company necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

The Company’s management, including its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of ~~September~~June 30, ~~2023~~2024, and concluded that the Company’s ~~disclosure~~ disclosure controls and procedures were not effective as of ~~September~~June 30, ~~2023~~2024, due to a material weakness in the Company’s internal control over financial reporting.

The Company has an ineffective control environment due to a lack of internal resources with expertise to determine entries and disclosures related to some of the Company’s more complex equity transactions. Management believes this lack of internal expertise has been historically mitigated by continuing to retain consultants with this expertise when needed. The Company expects that this material weakness will be further remediated with future capital raises.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation during the quarter ended ~~September~~June 30, ~~2023~~2024 that have materially affected, or that are reasonably likely to materially affect, the Company’s internal control over financial reporting.

2523

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company is not a party to any pending legal proceeding, nor is the Company’s property the subject of a pending legal proceeding. None of the Company’s directors, officers or affiliates are involved in a proceeding adverse to our business or has a material interest adverse to the Company’s business.

ITEM 1A. RISK FACTORS.

AsNot arequired for smaller reporting company, the Company is not required to disclose material changes to the risk factors that were contained in the Company’s Form 10 registration statement originally filed with the SEC on February 12, 2020, as amended (the “Form 10”)companies. However, in light of the recent coronavirus (COVID-19) pandemic, set forth below is a risk factor relating to COVID-19. Other than as set forth below, as of the filing date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors faced by the Company from those previously disclosed in the Form 10.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit No.		Description
31.1		Section 302 Certification of Principal Executive Officer*
31.2		Section 302 Certification of Principal Financial Officer*
32.1		Section 906 Certification of Principal Executive Officer and Principal Financial Officer***
101.INS		Inline XBRL Instance Document *
101.SCH		Inline XBRL Taxonomy Extension Schema Document *
101.CAL		Inline XBRL Taxonomy Calculation Linkbase Document **
101.LAB		Inline XBRL Taxonomy Labels Linkbase Document *
101.PRE		Inline XBRL Taxonomy Presentation Linkbase Document **
101.DEF		Inline XBRL Definition Linkbase Document *
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)*

*	Filed herewith.
**	This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

2624

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: ~~November~~January 1410, ~~2023~~2025

	Vicapsys Life Sciences, Inc.

	By:	/s/ Federico Pier
		Federico Pier
		Chief Executive Officer and Executive Chairman of the Board
		(Principal Executive Officer)

	By:	/s/ Jeffery Wright
		Jeffery Wright
		Chief Financial Officer
		(Principal Financial Officer and
		Principal Accounting Officer)

2725

Filing Compare · Vicapsys Life Sciences, Inc.